News – Page 541 – Endpoints News

Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug

4 years ago

Acadia's prized pain drug from $52M buyout flops its first test

4 years ago

Regeneron buys Art Krieg’s biotech startup for a discount price, boosting I/O pipeline

4 years ago

Enhertu nabs priority review for NSCLC as AstraZeneca and Daiichi Sankyo continue charting a blockbuster course

4 years ago

The 20(+1) under 40: Your guide to the next generation of biotech leaders

4 years ago

Sounds of Sanofi: Pills spinning, machines whirring aim to introduce ASMR — and showcase lab quality

4 years ago

AstraZeneca's Alexion to take new R&D space in biotech tower in New Haven

4 years ago

Amgen and AstraZeneca debut first Tezspire campaign with diverse cast of animated characters

4 years ago

Developing non-opioid pain drugs: Companies question if FDA is raising the bar

4 years ago

J&J reaches $99M opioid settlement with West Virginia, gets cleared to exit opioid liability lawsuit

4 years ago

War in Ukraine may require significant trial changes, EMA says in new guidance

4 years ago

When OS is the 'ultimate safety endpoint': FDA leaders question single-arm trials amid scrutiny of PI3K drugs for ...

4 years ago

A potential target for Alzheimer's treatment? Researchers unearth new immune response pathway

4 years ago

Bristol Myers inks $11M deal to settle anticompetitive claims in HIV suit

4 years ago

A medtech company's SPAC merger falls flat, missing on nine-figure valuation

4 years ago

Imara reduced to six employees as the biotech, once again preclinical, explores its options

4 years ago

Foresite's Jim Tananbaum yanks $250M SPAC, as an RA-backed Oxford spinout braves the choppy IPO waters

4 years ago

With more than 30 oncology partners, Gilead lays out its 2030 vision of 20 new approvals

4 years ago

Guest column: What happened with Esperion — and what defines success or failure?

4 years ago

Hit by 2 more flops, Bristol Myers and Nektar wind down IL-2/PD-1 program at the center of $3.6B deal

4 years ago

TG Therapeutics withdraws U2 application — and its component's approvals — one week before adcomm

4 years ago

Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M

4 years ago

Zooming in on a biotech layoff; $1.9B buyout to fill M&A void; Covid winners appoint new finance chiefs; and more

4 years ago

DOJ investigating Bausch Health over plaque psoriasis drug marketing — report

4 years ago

First page Previous page 538 539 540541542 543 544 Next page Last page